Quantcast

Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery

October 7, 2013

Reportbuyer.com just published a new market research report: Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery.

London (PRWEB) October 07, 2013

STUDY GOALS AND OBJECTIVES

This BCC Research report, Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery, provides an overview of the current overall state of ubiquitin proteasome market, focusing specifically on research tools, assay development, drug candidates and potential diagnostic applications. It describes existing drug pipelines and scientific platforms on the market, and provides a detailed analysis of the competitive environments, including new potential trends and markets for novel therapies and product development. This study includes information about significant players, trends and obstacles and other information affecting this market and its different sectors.

REASONS FOR DOING THIS STUDY

Ubiquitin proteasome system (UPS) represents one of the most studied and challenging areas in basic and applicable science. Indeed, the scientists who discovered this cellular phenomenon were awarded the Nobel Prize in Chemistry in 2004. Since 2004, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies.

However, despite the accumulation of basic knowledge about the mechanism of action of ubiquitination process and proteasome function, progress in drug screening and therapeutic development has been delayed. However, the proven success of the proteasome inhibitor Velcade (bortezomib) in addition to a recent breakthrough in the identification of new drug candidates in the UPS research field bring new excitement and hope for further successful drug development. Indeed, new second-generation proteasome inhibitor Kyprolis was recently approved by the FDA.

Moreover, the real commercial potential of this research area has not yet been fully acknowledged. Therefore, this study will provide knowledge of the current state of drug discovery in this field and new technologies in assay development and, more importantly, will describe potential novel commercial venues in diagnostics and drug development.

Overall, this report highlights the main segments in the ubiquitin proteasome market: reagents and technological platforms required for the research, drug discovery pipelines and potential applications of UPS in different areas of industry. It discusses its major players, current and future trends, and influences. Drivers and challenges in each segment of this industry are described in detail, including forecasts for the next five years.

SCOPE AND FORMAT

This report is essentially a business tool that can help market players evaluate properly new commercial opportunities in the ubiquitin proteasome space especially in the drug discovery, diagnostics and research tools submarkets. The geographic scope of this study is global. This market is generally complex and consists of a number of different segments, each of which is affected differently by scientific and technological developments. This report identifies the main positive and negative factors affecting each segment and forecasts market growth, future trends and product development in every major segment of this market.

METHODOLOGY AND INFORMATION SOURCES

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted.

In a second phase, a series of semi-structured interviews was conducted with company representatives, bench scientists, marketing representatives and other personnel at biotechnology and pharmaceutical companies. Other sources included academics, technology and consulting companies. Subsequent analysis of the documents and interviews notes was iterative.

INTENDED AUDIENCE

This report is intended for business development professionals, entrepreneurs, and other investors who need to fully understand and properly evaluate each segment in the market for ubiquitin proteasome drug discovery, diagnostics and research tools applications. It provides insight into the market position of major companies and shows new opportunities otherwise overlooked or less known to the business community.

ANALYST CREDENTIALS

Dr. Marianna Tcherpakov has more than eight years of experience as a bench scientist specializing in biochemistry, cell biology and industrial assay development. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with different research field trends and likely future developments.

REPORT HIGHLIGHTS

This report provides:

•An overview of the state of research tools, diagnostics, and drug discovery in the global ubiquitin proteasome (UPS) research field.

•Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.

•Discussion of existing products in the market.

•Identification of two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets.

•This study notes the trends that are going to affect further drug development in this area.

TABLE OF CONTENTS

CHAPTER 1 INTRODUCTION 2

STUDY GOALS AND OBJECTIVES 2

REASONS FOR DOING THIS STUDY 2

SCOPE AND FORMAT 2

METHODOLOGY AND INFORMATION SOURCES 3

INTENDED AUDIENCE 3

ANALYST CREDENTIALS 3

RELATED REPORTS 3

BCC ON-LINE SERVICES 4

DISCLAIMER 4

CHAPTER 2 SUMMARY 6

SUMMARY TABLE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND

DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 7

SUMMARY FIGURE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND

DEVELOPMENT, 2010-2018 ($ MILLIONS) 7

CHAPTER 3 SCIENTIFIC BACKGROUND AND SIGNIFICANCE OF UBIQUITIN

PROTEASOME RESEARCH 9

OVERVIEW 9

UBIQUITIN PROTEASOME SYSTEM: ITS MAJOR COMPONENTS AND ENZYMATIC PROCESS 9

FIGURE 1 SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION

REACTION 10

FIGURE 2 HIERARCHICAL STRUCTURE OF UBIQUITINE PROTEASOME SYSTEM 10

TABLE 1 ENZYMATIC COMPONENTS OF UBIQTUINATION/ DEUBIQUITINATION

REACTION 11

Chain Topology and its Significance in Cellular Function 11

PROTEASOME MACHINERY 12

20S Core Particle 12

19S Core Particle 13

Protein Degradation Process 13

Proteasome as a Target for Drug Discovery 14

UBIQUITIN DOMAIN PROTEINS AND UBIQUITIN-LIKE MODIFIERS 15

TABLE 2 UBIQUITIN LIKE MODIFIERS (UBLS), THEIR FUNCTION AND ASSOCIATED

SUBSTRATES 15

CHAPTER 4 UBIQUITIN PROTEASOME SYSTEM AND DRUG DISCOVERY 18

PROTEASOME MACHINERY IN DRUG DISCOVERY 18

OVERVIEW 18

Velcade: the First Ubiquitin Proteasome System Product 18

Chemical Structure of Velcade and Its Mechanism of Action 18

FIGURE 3 CHEMICAL STRUCTURE OF BORTEZOMIB 19

Pharmacodynamics, Administration and Side Effects 19

Velcade Sales Market 21

TABLE 3 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2011 21

Multiple Myeloma Symptoms and Treatment 21

TABLE 4 MARKET SIZE FOR MULTIPLE MYELOMA DRUG MARKET, THROUGH 2018 ($

BILLIONS) 22

NHL and Mantle Cell Lymphoma 23

Treatments for Mantle Cell Lymphoma and Other NHL 23

Current Major Market Participants in MM Treatment and Sales

Forecast 24

Millennium Pharmaceuticals (a Subsidiary of Takeda) 24

TABLE 5 EXAMPLE OF COST OF SIDE EFFECT FOR CHEMOTHERAPY TREATMENT IN

2006 IN U.S. PER PATIENT ($ THOUSANDS) 25

TABLE 6 U.S. AND WORLDWIDE NET SALES FOR VELCADE, THROUGH 2018 ($

MILLIONS) 26

FIGURE 4 U.S. AND WORLDWIDE NET SALES FOR VELCADE, 2009-2018 ($ MILLIONS) 26

Celgene 27

Revlimid 27

Thalomid 28

TABLE 7 NET SALES FOR REVLIMID AND THALOMID, THROUGH 2018 ($ MILLIONS) 28

FIGURE 5 NET SALES FOR REVLIMID AND THALOMID, 2009-2018 ($ MILLIONS) 29

Pomalyst 29

Onyx Pharmaceuticals 30

Kyprolis 30

TABLE 8 NET SALES FOR KYPROLIS, THROUGH 2018 ($ MILLIONS) 31

FIGURE 6 NET SALES FOR KYPROLIS, 2011-2018 ($ MILLIONS) 31

Market Shares of Millennium/Takeda, Celgene and Other Companies' Drugs 32

TABLE 9 MARKET SHARE BETWEEN CELGENE AND MILLENIUM

PHARMACEUTICALS/TAKEDA AND OTHER DRUG COMPANIES IN 2009, 2012

AGAINST POSSIBLE MARKET SHARE IN 2016 AND AFTER 33

New Indications for Velcade and Second-Generation Proteasome Inhibitors from Millenium/Takeda 34

TABLE 10 CURRENT R &D ACTIVITY IN UBIQUITIN/PROTEASOME RESEARCH IN

MILLENIUM PHARMACEUTICALS 35

COMPANIES WORKING ON SECOND-GENERATION PROTEASOME

INHIBITORS 36

Current Market Participants 36

TABLE 11 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET 37

Millennium Pharmaceuticals (a Subsidiary of Takeda) 37

Onyx Pharmaceuticals 37

Onx- 0912/Oprozomib 37

Onx-0914 38

TABLE 12 GENERAL MARKET WORTH FOR AUTOIMMUNE DISORDERS: LUPUS,

RHEUMATOID ARTHRITIS AND IBD IN 2010 ($ BILLIONS) 38

Cephalon (Teva) 38

CEP-18770/Delanzomib 38

Nereus Pharmaceuticals 39

NPI-0052/Marizomib 39

19S Inhibitors as Therapeutic Targets 39

ADDITIONAL MARKETS AND POTENTIAL THERAPEUTIC APPLICATIONS FOR

PROTEASOME ACTIVATORS/INHIBITORS 40

Proteasome Inhibitors in Treatment of Organ Transplant Patients 40

Autoimmune Diseases and Proteasome Inhibition 40

Anti – Inflammatory Activity of Proteasome Inhibitors 41

TABLE 13 ACTIVITY OF PROTEASOME INHIBITORS IN ANIMAL MODELS FOR

AUTOIMMUNE AND INFLAMMATORY DISEASES 41

Treatment of Reperfusion Injury after Stroke 42

Stimulation of Bone and Hair Growth by Proteasome Inhibitors 42

TABLE 14 MARKET SIZE FOR HAIR LOSS TREATMENT IN THE U.S. ($ BILLIONS) 43

Proteasome Activity Modulators as Skin Care and Cosmetic

Treatment 43

TABLE 15 GLOBAL MARKET SIZE FOR ANTI-AGING PRODUCTS ($ BILLIONS) 44

Proteasome Inhibitors as Anti-infectives 44

TABLE 16 STATISTICS FOR TUBERCULOSIS INFECTION WORLDWIDE AND IN THE

U.S., 2009 (MILLIONS) 45

TABLE 17 POTENTIAL MARKET WORTH FOR TUBERCULOSIS DRUG TREATMENT,

2009-2017 ($ MILLIONS) 46

Proteasome Inhibition as Dry Eye Treatment 46

TABLE 18 MARKET SIZE FOR DRY EYE TREATMENT, 2009 AND 2013 ($ BILLIONS) 46

UBIQUITINATION ENZYMES AS A TARGET FOR DRUG DISCOVERY 47

E1 LIGASE AS A TARGET FOR DRUG DISCOVERY 47

TABLE 19 CURRENT DRUG DISCOVERY FOR E1 INHIBITORS 47

Pyr-41, the First E1 Inhibitor 47

Nae-E1 Ligase for Neddylation as a Drug Target 48

MLN4924- NAE-1 Inhibitor by Millennium Pharmaceuticals

(Takeda) 48

Benzothiazole/Thiazole Pyridine 49

E2 LIGASE AS A TARGET FOR DRUG DISCOVERY 49

TABLE 20 E2S AS A DRUG DISCOVERY TARGET AND ITS MARKET POTENTIAL ($

BILLIONS) 51

Blood Disorders Market for E2s 51

Ube2T: Fanconi Anemia 51

Spectrin Sickle-Cell Disease (SCD) 51

TABLE 21 MARKET POTENTIALS FOR SCA TREATMENT 52

Oncology and the Immune Disorders Market for E2s 52

Role of UbcH10 in Cancer 52

Ubc13 Cancer/Immune Disorders 53

Neurodegenerative Disorders Market for E2s 54

E2-25K Alzheimer's and Huntington's Diseases 54

E2s as Target for Plant Biotechnology 54

E3 LIGASES AS A DRUG DISCOVERY TARGET 54

TABLE 22 COMPANIES THAT WORK ON E3 LIGASES AS A DRUG TARGET 55

Overview of Companies Working on E3 Ligases as Drug Targets 55

Aegera Therapeutics (Pharmascience) 55

AEG35156 55

AEG40826 (HGS1029) 56

AEGXXXX 57

Amgen 57

Aprea AB 58

Ascenta Therapeutics 58

Celgene 59

Elan Pharmaceuticals 59

Genentech (Hoffmann La Roche) 59

Hoffman La Roche 60

Johnson & Johnson (Ortho Biotech Oncology Research and Development) 61

Novartis 61

Priaxon AG 62

Progenra 62

Proteologics 63

Rigel Pharmaceuticals 64

TetraLogic Pharmaceuticals 64

HDM2 as a Target for Drug Discovery 64

TABLE 23 DRUG DISCOVERY APPROACH FOR P53 STUDIES 65

TABLE 24 COMPANIES WITH R&D IN P53 GENE THERAPY 66

Head and Neck Cancer as a Market Target for p53 Therapy 66

Ovarian Cancer as a Market Target for p53 Therapy 67

TABLE 25 U.S. STATISTICS AND GLOBAL MARKET SIZE FOR HEAD AND NECK AND

OVARIAN CANCERS, 2009 ($ MILLIONS) 67

HDM2-p53 Strategy for Drug Discovery 67

TABLE 26 STRATEGIES FOR HDM2-P53 DRUG DISCOVERY 68

TABLE 27 LIST OF COMPANIES AND DRUG CANDIDATES IN HDM2/P53 DRUG

DISCOVERY 69

The IAP Family as a Target for Drug Discovery 70

TABLE 28 CURRENT COMPANIES WITH R&D PROGRAM IN IAP DRUG DISCOVERY 71

TABLE 29 POTENTIAL MARKETS SIZE FOR IAPS DRUG DISCOVERY ($ BILLIONS) 73

Additional E3 Ubiquitin Ligases as Targets for Drug Discovery 73

TABLE 30 LIST OF E3 UBIQUITIN LIGASES IN DRUG DISCOVERY 73

APC Ligase Complex 74

SCF Complex 74

TRAF6 75

MuRF1 75

IDOL 75

Parkin 76

HRD1 76

TABLE 31 STATISTICS FOR RA IN THE U.S. AND GLOBAL ESTIMATE FOR RA MARKET,

2009 AND 2030 ($ BILLIONS) 76

POSH1 77

SMURF1 77

TABLE 32 STATISTICS FOR OSTEOPOROSIS IN THE U.S. AND GLOBAL ESTIMATE

FOR OSTEOPOROSIS MARKET ($ BILLIONS) 77

Cereblon 78

Midline-1 78

RNF146 and Bmi/Ring1B 78

TABLE 33 POTENTIAL MARKETS FOR CURRENT PROJECTS IN E3 LIGASE DRUG

DISCOVERY ($ BILLIONS) 79

Additional E3 Ligases as Potential Drug Targets 79

TABLE 34 ADDITIONAL E3 LIGASES AS POTENTIAL DRUG DISCOVERY TARGETS 79

AO7 80

Trim25 80

BRCA1 80

pVHL 80

E6-AP 80

LUBAC 80

TABLE 35 BREAST CANCER STATISTICS IN WOMEN IN THE U.S., 2009 (NUMBER OF

NEW CASES) 81

TABLE 36 MARKET FOR BREAST CANCER THERAPEUTICS, THROUGH 2016 ($

BILLIONS) 82

Companies with a Wide General Platform for Drug Discovery in

Ubiquitin-proteasome Systems 82

DEUBIQUITINASES AS A TARGET FOR DRUG DISCOVERY 83

OVERVIEW 83

TABLE 37 DEUBIQUITINASES AND THEIR ROLE IN CLINICAL CONDITIONS 83

POTENTIAL MARKETS BY DISEASE TYPE 84

Cancer 84

Neurodegeneration 84

Hematological Disorders 85

Virus Infections 85

Bacterial Infections 85

TABLE 38 EXAMPLES OF POTENTIAL MARKETS FOR DUBS DRUG DISCOVERY ($ BILLIONS) 86

TABLE 39 EXAMPLES OF DUBS INHIBITORS AND THEIR TARGETS 87

COMPANIES THAT WORK ON DUBS AS A DRUG TARGET 88

TABLE 40 COMPANIES WORKING ON DUBS AS DRUG TARGET 89

CellCentric 89

Cleave Biosciences 89

Genentech 90

Hybrigenics 90

Mission Therapeutics 90

Novartis 91

TABLE 41 STATISTICS AND COST OF MEDICAL CARE IN LUNG AND COLON CANCER

IN THE U.S., 2009 ($ BILLIONS) 91

Progenra 92

Proteostasis Therapeutics 92

UBIQUITIN-LIKE MODIFIERS AS TARGETS FOR DRUG DISCOVERY 93

Sumoylation Modification as a Drug Target Strategy 93

TABLE 42 ENZYMATIC MACHINERY OF SUMOYLATION 94

ISG15 Modification as a Drug Target Strategy 94

NEDDYLATION MODIFICATION AS A DRUG TARGET STRATEGY 95

CHAPTER 5 THE UBIQUITIN PROTEASOME SYSTEM AS A DIAGNOSTIC TOOL 97

OVERVIEW 97

TABLE 43 GLOBAL BIOMARKERS MARKET, THROUGH 2015 ($ BILLIONS) 98

TABLE 44 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO DIFFERENT

RESEARCH AREAS, 2013 ($ BILLIONS/%) 98

CANCER BIOMARKERS 98

CARDIOVASCULAR DISEASE BIOMARKERS 99

CNS DISORDERS BIOMARKERS 100

THE UBIQUITIN PROTEASOME SYSTEM AS A POTENTIAL DIAGNOSTIC TOOL 100

TABLE 45 ANALYSIS OF SCIENTIFIC PUBLICATION ON UBIQUITIN PROTEASOME

SYSTEM 101

UPS and Cancer Diagnostics 101

TABLE 46 MARKET FOR BREAST CANCER DIAGNOSTICS, THROUGH 2016 ($

BILLIONS) 103

UPS and Immune Disorder Diagnostics 103

TABLE 47 WORLDWIDE STATISTICS AND GLOBAL MARKET SIZE FOR MULTIPLE

SCLEROSIS AND RHEUMATOID ARTHRITIS 103

TABLE 48 MARKET FOR IMMUNE DISORDERS DIAGNOSTICS ($ BILLIONS) 105

UPS and Neurodegenerative Disorders Diagnostics 105

TABLE 49 MARKET SIZE FOR REPRESENTATIVE NEURODEGENARATION DISORDERS

AND STATISTICS OF INCIDENCE IN THE U.S. 106

TABLE 50 NET SALES OF REQUIP, 2010-2012 ($ MILLIONS) 107

TABLE 51 NET SALES OF NAMENDA IN THE LAST THREE YEARS, 2010-2012 ($ MILLIONS) 108

TABLE 52 STATISTICS FOR HUNTIGNTON CONDITION IN THE U.S. AND GLOBAL

MARKET SIZE FOR HUNTINGTON’S DISEASE 108

UPS as a Diagnostic Tool in Other Pathologies 109

Inflammatory Bowel Disease 109

TABLE 53 STATISTICS AND COST OF IBD IN THE U.S. 110

Biomarkers for Hepatocellular Carcinoma (HCC) in Cirrhosis

Patients 110

TABLE 54 STATISTICS AND COST OF HCC IN USA 110

CHAPTER 6 REAGENTS AND ASSAY DEVELOPMENT FOR UPS RESEARCH AND DRUG

DISCOVERY 113

OVERVIEW 113

CURRENT MARKET PARTICIPANTS 113

TABLE 55 COMPANIES INVOLVED IN MARKETING OF RESEARCH TOOLS FOR UPS,

NUMBER OF PRODUCTS AND REVENUE OF THE COMPANY, 2010 (UNITS/$ MILLIONS) 113

Boston Biochem 114

Enzo Life Sciences 114

LifeSensors 114

Life Technologies (Thermo Fisher Scientific) 114

Meso Scale Discovery 115

Millipore (EMD4Biosciences) 115

UbiQ 115

Ubiquigent 115

Additional Market Participants 116

TABLE 56 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF

UPS REAGENT TOOL COMPANIES ($) 117

FIGURE 7 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF

UPS REAGENT TOOL COMPANIES ($) 117

ASSAY DEVELOPMENT FOR UPS DRUG DISCOVERY 117

TABLE 57 PROVIDERS OF SCREENING ASSAY TOOLS 118

Current Market Participants in Assay Development for UPS Research 118

LanthaScreen Technology for Ubiquitination/Deconjugation

Assays 118

AlphaScreen Approach for Ubiquitination/Deconjugation Assays 119

Cisbio Bioassays 119

Meso Scale Discovery 120

LifeSensors 120

Promega 121

BioGenova 121

Ubiquigent 121

Ubiquitin as a Research Tool for Other Drug Discovery Opportunities 122

TABLE 58 COMPANIES SELLING UBIQUITIN AND UBIQUITIN-LIKE MODIFIERS AS

REAGENT TOOL FOR OTHER DRUG DISCOVERIES APPLICATIONS 123

Scil Proteins 123

Dualsystems Biotech 124

LifeSensors 124

Life Technologies (Thermo Fisher Scientific) 125

CHAPTER 7 MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT AND

SIGNIFICANCE OF PATENTS 127

MAIN MILESTONES IN UBIQUITIN-PROTEASOME MARKET DEVELOPMENT 127

TABLE 59 SCIENTIFIC AND TECHNOLOGICAL BREAKTHROUGHS IN UPS, 1977-2012 127

PROTEASOME DISCOVERY AS A SCIENTIFIC BREAKTHROUGH 128

NEW DEVELOPMENTS IN UPS DRUG DISCOVERY 128

NEW MARKET OPPORTUNITIES FOR UPS: PLANT BIOTECHNOLOGY AS A

POTENTIAL MARKET FOR UPS 129

TABLE 60 MARKET VALUE OF COTTON AND CORN IN THE U.S. ($ BILLIONS) 130

SIGNIFICANCE OF PATENTS IN UPS RESEARCH 130

TABLE 61 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING

2012 131

TABLE 62 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING

2006 132

TABLE 63 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/ PROTEASOME

RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013 133

FIGURE 8 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/PROTEASOME

RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013

(NUMBER)

134

TABLE 64 PERCENTAGES OF PATENT APPLICATIONS IN UPS RESEARCH FILED IN

THE U.S., EUROPE AND JAPAN (%) 134

CHAPTER 8 MARKET SUMMARY 137

TABLE 65 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, THROUGH 2018 ($

MILLIONS) 137

FIGURE 9 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, 2010-2018 ($

MILLIONS) 138

TABLE 66 DIFFERENT TARGETS OF UPS IN CURRENT DRUG DEVELOPMENT

COMPANIES 139

TABLE 67 REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG

DISCOVERY 139

CHAPTER 9 SELECT COMPANIES AND PROFILES 142

CELGENE CORPORATION 142

ELAN PHARMACEUTICALS 143

GENENTECH (HOFFMANN-LA ROCHE AG) 144

F. HOFFMANN-LA ROCHE LTD. 145

JOHNSON & JOHNSON 146

MILLENNIUM PHARMACEUTICALS: THE TAKEDA ONCOLOGY COMPANY 147

ONYX PHARMACEUTICALS INC. 147

PROGENRA 148

PROTEOLOGICS LTD. 149

PROTEOLOGICS LTD. (U.S.) 149

UBIQUIGENT LTD. 149

CHAPTER 10 LIST OF COMPANIES MENTIONED IN REPORT 152

ACENTA THERAPEUTICS 152

AEGERA THERAPEUTICS INC. (PART OF PHARMASCIENCE INC.) 152

AMGEN INC. 152

ASTELLAS PHARMA U.S. INC. 152

BIOGENOVA CORP. 152

BOSTON BIOCHEM INC. (R&D SYSTEMS) 153

BRISTOL-MYERS SQUIBB 153

CELGENE CORPORATION 153

CELLCENTRIC LTD. 153

CELLXPLORE 153

CISBIO 154

CLEAVE BIOSCIENCES 154

DUALSYSTEMS BIOTECH AG 154

ELAN PHARMACEUTICAL 154

ENZO LIFE SCIENCES INC. 154

GENENTECH INC. (ROCHE GROUP) 155

GSK (GLAXOSMITHKLINE PLC) 155

HYBRIGENICS 155

JOHNSON AND JOHNSON 155

F. HOFFMANN-LA ROCHE AG 155

LIFE SENSORS INC. 156

LIFE TECHNOLOGIES CORP. (THERMO FISHER SCIENTIFIC) 156

MESO SCALE DISCOVERY 156

MERCK CORPORATE HEADQUARTERS 156

MILLENIUM PHARMACEUTICAL (THE TAKEDA ONCOLOGY COMPANY) 156

MISSION THERAPEUTICS LTD. 157

NEXUSPHARMA INC. 157

NOVARTIS INTERNATIONAL AG 157

ONYX PHARMACEUTICALS INC. 157

PRIAXON AG 157

PROGENRA INC. 158

PROTEOLOGICS LTD. 158

PROTEOSTASIS THERAPEUTICS 158

RIGEL PHARMACEUTICALS INC. 158

SCIL PROTEINS GMBH 158

SIGMA-ALDRICH 159

THERMO FISHER SCIENTIFIC INC. 159

TEVA PHARMACEUTICALS 159

TETRALOGICS PHARMACEUTICALS 159

UBIQ BIO BV 159

UBIQUIGENT LTD. 160

LIST OF TABLES

SUMMARY TABLE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND

DEVELOPMENT, THROUGH 2018 ($ MILLIONS) 7

TABLE 1 ENZYMATIC COMPONENTS OF UBIQTUINATION/ DEUBIQUITINATION

REACTION 11

TABLE 2 UBIQUITIN LIKE MODIFIERS (UBLS), THEIR FUNCTION AND ASSOCIATED

SUBSTRATES 15

TABLE 3 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2011 21

TABLE 4 MARKET SIZE FOR MULTIPLE MYELOMA DRUG MARKET, THROUGH 2018 ($

BILLIONS) 22

TABLE 5 EXAMPLE OF COST OF SIDE EFFECT FOR CHEMOTHERAPY TREATMENT IN

2006 IN U.S. PER PATIENT ($ THOUSANDS) 25

TABLE 6 U.S. AND WORLDWIDE NET SALES FOR VELCADE, THROUGH 2018 ($

MILLIONS) 26

TABLE 7 NET SALES FOR REVLIMID AND THALOMID, THROUGH 2018 ($ MILLIONS) 28

TABLE 8 NET SALES FOR KYPROLIS, THROUGH 2018 ($ MILLIONS) 31

TABLE 9 MARKET SHARE BETWEEN CELGENE AND MILLENIUM

PHARMACEUTICALS/TAKEDA AND OTHER DRUG COMPANIES IN 2009, 2012 AGAINST

POSSIBLE MARKET SHARE IN 2016 AND AFTER

33

TABLE 10 CURRENT R &D ACTIVITY IN UBIQUITIN/PROTEASOME RESEARCH IN

MILLENIUM PHARMACEUTICALS 35

TABLE 11 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG

TARGET 37

TABLE 12 GENERAL MARKET WORTH FOR AUTOIMMUNE DISORDERS: LUPUS,

RHEUMATOID ARTHRITIS AND IBD IN 2010 ($ BILLIONS) 38

TABLE 13 ACTIVITY OF PROTEASOME INHIBITORS IN ANIMAL MODELS FOR

AUTOIMMUNE AND INFLAMMATORY DISEASES 41

TABLE 14 MARKET SIZE FOR HAIR LOSS TREATMENT IN THE U.S. ($ BILLIONS) 43

TABLE 15 GLOBAL MARKET SIZE FOR ANTI-AGING PRODUCTS ($ BILLIONS) 44

TABLE 16 STATISTICS FOR TUBERCULOSIS INFECTION WORLDWIDE AND IN THE

U.S., 2009 (MILLIONS) 45

TABLE 17 POTENTIAL MARKET WORTH FOR TUBERCULOSIS DRUG TREATMENT,

2009-2017 ($ MILLIONS) 46

TABLE 18 MARKET SIZE FOR DRY EYE TREATMENT, 2009 AND 2013 ($ BILLIONS) 46

TABLE 19 CURRENT DRUG DISCOVERY FOR E1 INHIBITORS 47

TABLE 20 E2S AS A DRUG DISCOVERY TARGET AND ITS MARKET POTENTIAL ($

BILLIONS) 51

TABLE 21 MARKET POTENTIALS FOR SCA TREATMENT 52

TABLE 22 COMPANIES THAT WORK ON E3 LIGASES AS A DRUG TARGET 55

TABLE 23 DRUG DISCOVERY APPROACH FOR P53 STUDIES 65

TABLE 24 COMPANIES WITH R&D IN P53 GENE THERAPY 66

TABLE 25 U.S. STATISTICS AND GLOBAL MARKET SIZE FOR HEAD AND NECK AND

OVARIAN CANCERS, 2009 ($ MILLIONS) 67

TABLE 26 STRATEGIES FOR HDM2-P53 DRUG DISCOVERY 68

TABLE 27 LIST OF COMPANIES AND DRUG CANDIDATES IN HDM2/P53 DRUG

DISCOVERY 69

TABLE 28 CURRENT COMPANIES WITH R&D PROGRAM IN IAP DRUG DISCOVERY 71

TABLE 29 POTENTIAL MARKETS SIZE FOR IAPS DRUG DISCOVERY ($ BILLIONS) 73

TABLE 30 LIST OF E3 UBIQUITIN LIGASES IN DRUG DISCOVERY 73

TABLE 31 STATISTICS FOR RA IN THE U.S. AND GLOBAL ESTIMATE FOR RA MARKET,

2009 AND 2030 ($ BILLIONS) 76

TABLE 32 STATISTICS FOR OSTEOPOROSIS IN THE U.S. AND GLOBAL ESTIMATE FOR

OSTEOPOROSIS MARKET ($ BILLIONS) 77

TABLE 33 POTENTIAL MARKETS FOR CURRENT PROJECTS IN E3 LIGASE DRUG

DISCOVERY ($ BILLIONS) 79

TABLE 34 ADDITIONAL E3 LIGASES AS POTENTIAL DRUG DISCOVERY TARGETS 79

TABLE 35 BREAST CANCER STATISTICS IN WOMEN IN THE U.S., 2009 (NUMBER OF

NEW CASES) 81

TABLE 36 MARKET FOR BREAST CANCER THERAPEUTICS, THROUGH 2016 ($

BILLIONS) 82

TABLE 37 DEUBIQUITINASES AND THEIR ROLE IN CLINICAL CONDITIONS 83

TABLE 38 EXAMPLES OF POTENTIAL MARKETS FOR DUBS DRUG DISCOVERY ($

BILLIONS) 86

TABLE 39 EXAMPLES OF DUBS INHIBITORS AND THEIR TARGETS 87

TABLE 40 COMPANIES WORKING ON DUBS AS DRUG TARGET 89

TABLE 41 STATISTICS AND COST OF MEDICAL CARE IN LUNG AND COLON CANCER

IN THE U.S., 2009 ($ BILLIONS) 91

TABLE 42 ENZYMATIC MACHINERY OF SUMOYLATION 94

TABLE 43 GLOBAL BIOMARKERS MARKET, THROUGH 2015 ($ BILLIONS) 98

TABLE 44 WORLDWIDE MARKET FOR BIOMARKERS ACCORDING TO DIFFERENT

RESEARCH AREAS, 2013 ($ BILLIONS/%) 98

TABLE 45 ANALYSIS OF SCIENTIFIC PUBLICATION ON UBIQUITIN PROTEASOME

SYSTEM 101

TABLE 46 MARKET FOR BREAST CANCER DIAGNOSTICS, THROUGH 2016 ($ BILLIONS) 103

TABLE 47 WORLDWIDE STATISTICS AND GLOBAL MARKET SIZE FOR MULTIPLE

SCLEROSIS AND RHEUMATOID ARTHRITIS 103

TABLE 48 MARKET FOR IMMUNE DISORDERS DIAGNOSTICS ($ BILLIONS) 105

TABLE 49 MARKET SIZE FOR REPRESENTATIVE NEURODEGENARATION DISORDERS

AND STATISTICS OF INCIDENCE IN THE U.S. 106

TABLE 50 NET SALES OF REQUIP, 2010-2012 ($ MILLIONS) 107

TABLE 51 NET SALES OF NAMENDA IN THE LAST THREE YEARS, 2010-2012 ($

MILLIONS) 108

TABLE 52 STATISTICS FOR HUNTIGNTON CONDITION IN THE U.S. AND GLOBAL

MARKET SIZE FOR HUNTINGTON’S DISEASE 108

TABLE 53 STATISTICS AND COST OF IBD IN THE U.S. 110

TABLE 54 STATISTICS AND COST OF HCC IN USA 110

TABLE 55 COMPANIES INVOLVED IN MARKETING OF RESEARCH TOOLS FOR UPS,

NUMBER OF PRODUCTS AND REVENUE OF THE COMPANY, 2010 (UNITS/$ MILLIONS) 113

TABLE 56 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF

UPS REAGENT TOOL COMPANIES ($) 117

TABLE 57 PROVIDERS OF SCREENING ASSAY TOOLS 118

TABLE 58 COMPANIES SELLING UBIQUITIN AND UBIQUITIN-LIKE MODIFIERS AS

REAGENT TOOL FOR OTHER DRUG DISCOVERIES APPLICATIONS 123

TABLE 59 SCIENTIFIC AND TECHNOLOGICAL BREAKTHROUGHS IN UPS, 1977-2012 127

TABLE 60 MARKET VALUE OF COTTON AND CORN IN THE U.S. ($ BILLIONS) 130

TABLE 61 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING

2012 131

TABLE 62 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES DURING

2006 132

TABLE 63 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/ PROTEASOME

RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013 133

TABLE 64 PERCENTAGES OF PATENT APPLICATIONS IN UPS RESEARCH FILED IN THE

U.S., EUROPE AND JAPAN (%) 134

TABLE 65 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, THROUGH 2018 ($

MILLIONS) 137

TABLE 66 DIFFERENT TARGETS OF UPS IN CURRENT DRUG DEVELOPMENT

COMPANIES 139

TABLE 67 REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG

DISCOVERY 139

LIST OF FIGURES

SUMMARY FIGURE GLOBAL MARKET FOR UBIQUITIN PROTEASOME RESEARCH AND

DEVELOPMENT, 2010-2018 ($ MILLIONS) 7

FIGURE 1 SCHEMATIC REPRESENTATION OF ENZYMATIC STEPS IN UBIQUITINATION

REACTION 10

FIGURE 2 HIERARCHICAL STRUCTURE OF UBIQUITINE PROTEASOME SYSTEM 10

FIGURE 3 CHEMICAL STRUCTURE OF BORTEZOMIB 19

FIGURE 4 U.S. AND WORLDWIDE NET SALES FOR VELCADE, 2009-2018 ($ MILLIONS) 26

FIGURE 5 NET SALES FOR REVLIMID AND THALOMID, 2009-2018 ($ MILLIONS) 29

FIGURE 6 NET SALES FOR KYPROLIS, 2011-2018 ($ MILLIONS) 31

FIGURE 7 EXAMPLE OF COMMON UPS REAGENTS PRICES IN MAJOR SUPPLIERS OF

UPS REAGENT TOOL COMPANIES ($) 117

FIGURE 8 NUMBER OF PATENT APPLICATIONS IN UBIQUITIN/PROTEASOME

RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2013 (NUMBER) 134

FIGURE 9 WORLDWIDE MARKET FOR VELCADE AND KYPROLIS, 2010-2018 ($

MILLIONS) 138

Read the full report:

Ubiquitin Proteasome: Global Markets for Research Tools, Diagnostics and Drug Discovery.

http://www.reportbuyer.com/pharma_healthcare/drug_discovery/ubiquitin_proteasome_global_markets_research_tools_diagnostics_drug_discovery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: http://www.reportbuyer.com/

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/10/prweb11202455.htm


Source: prweb



comments powered by Disqus